Norepinephrine potentiated compositions and method of use
OwnerFrank J. Macriinventor
Life of this patent
Estimating the term…
Abstract
Novel pharmaceutical compositions containing norepinephrine releasers such as alpha-adrenergic agonists, para-sympathomimetic agonists and carbonic anhydrase inhibitors in combination with a potentiating amount of norepinephrine are disclosed. Use of such compositions, exemplified by the combination of norepinephrine and epinephrine, in an ophthalmic solution for the treatment of glaucoma is also disclosed, as well as the use of the combination of norepinephrine and a norepinephrine releaser in the treatment of congestion in the upper respiratory tract.
Claims8
A pharmaceutical composition comprising:
- (1) 0.1-0.01 wt % isoproterenol or a pharmaceutically aceptable salt thereof;
- and (2) 0.0001-0.05 wt % 1-norepinephrine or a pharmaceutially acceptable salt thereof.
An opthalmic solution comprising:
- (1) 0.1-0.01 wt % isoproterenol or a pharmaceutically acceptable salt thereof;
- (2) 0.0001-0.05 wt % norepinephrine or a pharmaceutically acceptable salt thereof;
- and (3) a sterile, pharmaceutically acceptable liquid carrier.
A method for the treatment of glaucoma by simultaneously, topically administering to the eye a solution of 0.1-0.01 wt % isoproterenol or a pharmaeutically acceptable salt thereof and a solution of 0.0001-0.05 wt % norepinephrine or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.